Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Current Deferred Revenue (2016 - 2019)

Outlook Therapeutics (OTLK) has disclosed Current Deferred Revenue for 5 consecutive years, with $2.3 million as the latest value for Q2 2019.

  • On a quarterly basis, Current Deferred Revenue rose 5.8% to $2.3 million in Q2 2019 year-over-year; TTM through Jun 2019 was $2.3 million, a 5.8% increase, with the full-year FY2018 number at $1.7 million, down 43.69% from a year prior.
  • Current Deferred Revenue was $2.3 million for Q2 2019 at Outlook Therapeutics, roughly flat from $2.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $3.1 million in Q3 2017 to a low of $1.2 million in Q3 2016.
  • A 5-year average of $2.0 million and a median of $2.0 million in 2015 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 154.63% in 2017, then crashed 43.69% in 2018.
  • Outlook Therapeutics' Current Deferred Revenue stood at $2.0 million in 2015, then plummeted by 38.75% to $1.2 million in 2016, then skyrocketed by 126.82% to $2.8 million in 2017, then fell by 13.0% to $2.4 million in 2018, then decreased by 2.39% to $2.3 million in 2019.
  • Per Business Quant, the three most recent readings for OTLK's Current Deferred Revenue are $2.3 million (Q2 2019), $2.3 million (Q1 2019), and $2.4 million (Q4 2018).